Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AssayMetrics and Cambridge Research Biochemicals Collaborate

Published: Monday, October 08, 2012
Last Updated: Monday, October 08, 2012
Bookmark and Share
Collaboration in the field of Fluorescence Lifetime technology.

AssayMetrics Ltd has announced collaboration with Cambridge Research Biochemicals Ltd, the UK’s most established peptide and antibody company.

Fluorescence Lifetime is a new and assay technology used in the biochemical screening of new drugs in High Throughput Screening and compound characterization roles in the pharmaceutical industry.

The collaboration involves Cambridge Research Biochemicals making key peptide substrates labelled with AssayMetrics’ Fluorescence Lifetime dyes.

The peptides are used to screen novel drugs in equipment such as AssayMetrics’ Fluospec® FL reader and are employed in assays involving kinases, proteases, protein:protein interactions and other target enzyme systems.

The collaboration brings together two companies leading their respective fields to be able to offer solutions to the pharmaceutical industry enabling faster, more efficient and cheaper drug discovery and development, thereby improving the effectiveness of pharmaceutical R&D.

Dr Pierre Graves, MD of AssayMetrics Ltd commented, “This is exciting news as Cambridge Research Biochemicals have considerable expertise in making the type of complex peptides needed for innovative discovery.”

Emily Humphrys, Commercial Director of Cambridge Research Biochemicals was equally positive: “This technology has so much potential that we are really pleased to be collaborating with AssayMetrics at this early stage.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!